Scioto Biosciences

Scioto Biosciences is a clinical-stage biotechnology company developing microbiome-derived therapeutics targeting the gut-brain axis to treat serious neurological and neurodevelopmental disorders. The company's pipeline focuses on conditions with high unmet need including autism spectrum disorder (ASD), Fragile X syndrome, and related conditions. Scioto's approach leverages proprietary microbial strains and formulations that modulate neuroactive metabolites produced by the gut microbiome, aiming to improve behavioral and cognitive outcomes in patients where existing treatments are limited. Founded in 2018 and headquartered in Indianapolis, Indiana, the company has received funding to advance its pipeline toward clinical trials.